Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel therapies for AML: a round-up for clinicians.
Swaminathan M, Wang ES. Swaminathan M, et al. Expert Rev Clin Pharmacol. 2020 Dec;13(12):1389-1400. doi: 10.1080/17512433.2020.1850255. Epub 2021 Jan 7. Expert Rev Clin Pharmacol. 2020. PMID: 33412978 Review.
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. Swaminathan M, et al. Haematologica. 2021 Aug 1;106(8):2121-2130. doi: 10.3324/haematol.2020.263392. Haematologica. 2021. PMID: 33853292 Free PMC article. Clinical Trial.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Bataller A, et al. Among authors: swaminathan m. Lancet Haematol. 2024 Mar;11(3):e186-e195. doi: 10.1016/S2352-3026(23)00367-8. Epub 2024 Feb 2. Lancet Haematol. 2024. PMID: 38316133 Clinical Trial.
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.
Singh A, Mencia-Trinchant N, Griffiths EA, Altahan A, Swaminathan M, Gupta M, Gravina M, Tajammal R, Faber MG, Yan L, Sinha E, Hassane DC, Hayes DN, Guzman ML, Iyer R, Wang ES, Thota S. Singh A, et al. Among authors: swaminathan m. JCO Precis Oncol. 2022 Jan;6:e2100309. doi: 10.1200/PO.21.00309. JCO Precis Oncol. 2022. PMID: 35025619 Free PMC article.
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. Hampel PJ, et al. Among authors: swaminathan m. Blood Adv. 2024 May 28;8(10):2342-2350. doi: 10.1182/bloodadvances.2023012080. Blood Adv. 2024. PMID: 38537065 Free PMC article.
Hematologic malignancies and Li-Fraumeni syndrome.
Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Swaminathan M, et al. Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1):a003210. doi: 10.1101/mcs.a003210. Print 2019 Feb. Cold Spring Harb Mol Case Stud. 2019. PMID: 30709875 Free PMC article. Review.
605 results